stockrow
Saturday 7 November 2026
Export JANX’s income statement to Excel — free account
Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +12.8%
- Free cash flow
- −94.5%
Quarter to September 2026, against a year earlier
17.63
1.57
+9.78%
Follow JANX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | — | — |
+8 more TTM periods Free account |
| (10.58%) | (10.70%) | (11.72%) | (11.48%) | ||
| (9.94%) | (10.06%) | (11.01%) | (11.02%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(11.00%) | (11.07%) | (12.09%) | (11.90%) | |
Average Days of Receivables |
4.51 | 2.27 | 901.43 | — | |
Free Cash Flow per Share |
(0.86) | (0.67) | (1.25) | (1.34) | |
Free Cash Flow |
(54.16) | (41.92) | (78.49) | (83.28) | |
Capital Expenditures |
(0.58) | (0.67) | (0.94) | (1.04) | |
| Other line items | |||||
Cash ROIC |
(2.92%) | (2.21%) | (4.14%) | (4.33%) | |
Accounts Receivable Turnover |
71.59 | 25.96 | 0.78 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
360.24% | 516.60% | 900.75% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
128.96% | 181.55% | 303.85% | 0.00% | |
Share Based Compensation of Revenue |
109.29% | 153.71% | 273.69% | 0.00% | |
Operating CF/Net income |
0.54 | 0.40 | 0.68 | 0.72 | |
Depreciation/Fixed assets |
(3.76) | (3.61) | (3.95) | (4.04) | |
Capex/Depreciation |
0.06 | 0.06 | 0.07 | 0.07 | |
Revenue per Share |
0.53 | 0.38 | 0.23 | 0.00 | |
Operating CF per Share |
(0.85) | (0.66) | (1.24) | (1.33) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.02) | |
Capex to Sales |
0.02 | 0.03 | 0.07 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026